JP2023524434A5 - - Google Patents
Info
- Publication number
- JP2023524434A5 JP2023524434A5 JP2022565781A JP2022565781A JP2023524434A5 JP 2023524434 A5 JP2023524434 A5 JP 2023524434A5 JP 2022565781 A JP2022565781 A JP 2022565781A JP 2022565781 A JP2022565781 A JP 2022565781A JP 2023524434 A5 JP2023524434 A5 JP 2023524434A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- icam3
- cov
- sars
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017199P | 2020-04-29 | 2020-04-29 | |
| US63/017,199 | 2020-04-29 | ||
| PCT/US2021/029608 WO2021222385A1 (en) | 2020-04-29 | 2021-04-28 | Glucocorticoid receptor (gr) modulators for treating a sars-cov-2 virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524434A JP2023524434A (ja) | 2023-06-12 |
| JP2023524434A5 true JP2023524434A5 (cg-RX-API-DMAC7.html) | 2024-05-08 |
Family
ID=76270026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565781A Pending JP2023524434A (ja) | 2020-04-29 | 2021-04-28 | 新規療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230172950A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4142736A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023524434A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230015927A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115666583A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022021691A2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021222385A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021247000A1 (en) | 2020-06-01 | 2021-12-09 | Avm Biotechnology, Llc | Methods of treatment using icam-modulating agents |
| EP4426317A1 (en) * | 2021-11-05 | 2024-09-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation |
| CN114028571B (zh) * | 2021-11-18 | 2023-04-28 | 中国医学科学院基础医学研究所 | 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用 |
| CN114099481B (zh) * | 2022-01-28 | 2022-05-24 | 深圳湾实验室 | 雾化吸入型糖皮质激素纳米药物及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110475571B (zh) | 2017-04-01 | 2023-04-04 | Avm生物技术有限责任公司 | 细胞免疫疗法前细胞毒性预调理的替代 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| KR20220148859A (ko) * | 2020-02-28 | 2022-11-07 | 에이브이엠 바이오테크놀로지, 엘엘씨 | 림프구 집단 및 이를 생산하는 방법 |
-
2021
- 2021-04-28 US US17/921,128 patent/US20230172950A1/en active Pending
- 2021-04-28 CN CN202180031406.4A patent/CN115666583A/zh active Pending
- 2021-04-28 WO PCT/US2021/029608 patent/WO2021222385A1/en not_active Ceased
- 2021-04-28 JP JP2022565781A patent/JP2023524434A/ja active Pending
- 2021-04-28 EP EP21729980.9A patent/EP4142736A1/en active Pending
- 2021-04-28 BR BR112022021691A patent/BR112022021691A2/pt unknown
- 2021-04-28 KR KR1020227041735A patent/KR20230015927A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies | |
| Zhou et al. | Liver-resident NK cells control antiviral activity of hepatic T cells via the PD-1-PD-L1 axis | |
| Zhang et al. | Treg: a promising immunotherapeutic target in oral diseases | |
| Xia et al. | Activated regulatory T-cells attenuate myocardial ischaemia/reperfusion injury through a CD39-dependent mechanism. | |
| Almawi et al. | An alternate mechanism of glucocorticoid anti‐proliferative effect: promotion of a Th2 cytokine‐secreting profile | |
| Letafati et al. | Unraveling the dynamic mechanisms of natural killer cells in viral infections: insights and implications | |
| Wang et al. | Regulatory T cells in autoimmune hepatitis: unveiling their roles in mouse models and patients | |
| Gross et al. | Regulatory functions of natural killer cells in multiple sclerosis | |
| Cerwenka et al. | Natural killer cell memory in infection, inflammation and cancer | |
| Kin et al. | It takes nerve to tell T and B cells what to do | |
| Li et al. | The role of immune cells in chronic HBV infection | |
| Earle et al. | In vitro expanded human CD4+ CD25+ regulatory T cells suppress effector T cell proliferation | |
| Noble et al. | IFN-γ and IL-4 regulate the growth and differentiation of CD8+ T cells into subpopulations with distinct cytokine profiles | |
| Morgan et al. | Distinct effects of dexamethasone on human natural killer cell responses dependent on cytokines | |
| Calzada-Wack et al. | Interleukin-10 drives human monocytes to CD16 positive macrophages | |
| Qu et al. | Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients | |
| Thomson et al. | Prospective clinical testing of regulatory dendritic cells in organ transplantation | |
| JP2020515581A5 (cg-RX-API-DMAC7.html) | ||
| Luo et al. | CMV infection and CMV-specific immune reconstitution following haploidentical stem cell transplantation: an update | |
| Murphy et al. | The potential role of NK cells in the separation of graft‐versus‐tumor effects from graft‐versus‐host disease after allogeneic bone marrow transplantation | |
| KR20000010799A (ko) | 억제인자 세포 집단을 생성시키기 위한 인터루킨-10의 용도 | |
| Varanasi et al. | Azacytidine treatment inhibits the progression of herpes stromal keratitis by enhancing regulatory T cell function | |
| Ye et al. | Optimization of donor lymphocyte infusion for AML relapse after allo-HCT in the era of new drugs and cell engineering | |
| Duan et al. | Targeting NK cells for HIV-1 treatment and reservoir clearance | |
| Khil et al. | Human chorionic gonadotropin is an immune modulator and can prevent autoimmune diabetes in NOD mice |